Article Data

  • Views 497
  • Dowloads 119

Original Research

Open Access

Immunohistochemical analysis of heat shock proteins in triple negative breast cancer: HSP60 expression is a marker of poor prognosis

  • K. Bodoor1,†,*,
  • A. Abu-sheikha1,†
  • I. Matalka2
  • H. Alzou’bi2
  • O. Batiha1
  • A. Abu-Awad3
  • S.A. Jalboush1
  • L. M. Fayyad4
  • E. Qadiri4
  • Y. Jarun1
  • K. Albatayneh5
  • Y. Haddad6

1Department of Applied Biology, Jordan University of Science and Technology, Irbid, Jordan

2Department of Pathology and Laboratory Medicine, Jordan University of Science and Technology, Irbid, Jordan

3Department of Histopathology, King Hussein Medical Center, Amman, Jordan

4Department of Biological Sciences, Yarmouk University, Irbid, Jordan

5Department of Chemistry and Biochemistry, Faculty of Agronomy, Mendel University in Brno, Brno, Czech Republic

DOI: 10.12892/ejgo4347.2018 Vol.39,Issue 6,December 2018 pp.926-936

Published: 15 December 2018

*Corresponding Author(s): K. Bodoor E-mail: khaldon_bodoor@just.edu.jo

† These authors contributed equally.

Abstract

Triple negative breast cancer (TNBC) is an aggressive and rapidly growing subtype of breast cancer characterized by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) expression, rendering it resistant to targeted therapies. In the absence of molecular targets, the pathogenesis of TNBC is not well understood and many studies are focused towards identifying the pathways and molecular signatures associated with the initiation and progression of TNBC. Heat shock proteins emerged as key players in the tumorigenic pathways of several types of cancer including TNBC. In the present study, paraffinembedded tumor tissues of 66 Jordanian TNBC patients were analyzed, retrospectively, by immunohistochemistry to investigate the expression of HSP90, HSP70, HSP60, and HSP27 in Jordanian TNBC patients. The expression of the aforementioned markers was also examined using disease-free survival (DFS) along with a variety of clinical and pathological characteristics such as age, stage/grade of tumor, and nodal involvement. Positive expression of HSP90, HSP60, HSP27, and HSP70 was shown in 89%, 79%, 76%, and 40% of the cases analyzed, respectively. HSP60 positive expression was found to be significantly correlated with advanced stage (pT3/pT4) of the tumor (p = 0.05), nodal involvement (p = 0.03), and older age of patients (p = 0.03). Among the clinical and pathological variables analyzed in the present study, it was found that advanced stage (pT3/pT4) of the tumor and older age of the patients were significantly associated with worse DFS (p = 0.001 and 0.02, respectively). Additionally, positive expression of HSP60 showed to be correlated with worse DFS (p = 0.05). This study highlights the importance of HSP60 as a marker of poor prognosis in TNBC patients.

Keywords

Breast cancer; Heat shock protein; Immunohistochemistry; Prognosis.

Cite and Share

K. Bodoor,A. Abu-sheikha,I. Matalka,H. Alzou’bi,O. Batiha,A. Abu-Awad,S.A. Jalboush,L. M. Fayyad,E. Qadiri,Y. Jarun,K. Albatayneh,Y. Haddad. Immunohistochemical analysis of heat shock proteins in triple negative breast cancer: HSP60 expression is a marker of poor prognosis. European Journal of Gynaecological Oncology. 2018. 39(6);926-936.

References

[1] Siegel R.L., Miller K.D., Jemal A.: “Cancer statistics”. CA Cancer J Clin., 2016, 66, 7.

[2] Tarawneh, M., Nimri, O., Arkoob, K., AL Zaghal, M.: “Cancer incidence in Jordan 2009. Non-Communicable Diseases Directorate, Jordan Cancer Registry”. Ministry of Health, 2009.

[3] Abdel-Razeq H., Attiga F., Mansour A.: “Cancer care in Jordan”. Hematol Oncol Stem Cell Ther., 2015, 8, 64.

[4] Ani A., Shammout H., Domour A.: “Breast Cancer in Previously Lactating Women”. Arch Med., 2016, 8, 5.

[5] Abu-Helalah A.M., Alshraideh A.H., Al-Hanaqtah M.T., Da'na M., Al-Omari A., Mubaidin R.: “Delay in Presentation, Diagnosis, and Treatment for Breast Cancer Patients in Jordan”. Breast J., 2016, 22, 213.

[6] Sørlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., et al.: “Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications”. Proc. Natl. Acad. Sci. USA, 2001, 98, 10869.

[7] Pal S.K., Childs B.H., Pegram M.: “Triple negative breast cancer: unmet medical needs”. Breast Cancer Res Treat., 2011, 125, 627.

[8] Abramson V.G., Mayer I.A.: “Molecular heterogeneity of triple-negative breast cancer”. Curr. Breast Cancer Rep., 2014, 6, 154.

[9] Haffty B.G., Yang Q., Reiss M., Kearney T., Higgins S.A., Weidhaas J., Harris L., et al.: “Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer”. J. Clin. Oncol., 2006, 24, 5652.

[10] Reis-Filho J., Tutt A.: “Triple negative tumours: a critical review”. Histopathology, 2008, 52, 108.

[11] Rakha E.A., El-Sayed M.E., Green A.R., Lee A.H., Robertson J.F., Ellis I.O.: “Prognostic markers in triple-negative breast cancer”. Cancer, 2007, 109, 25-32.

[12] Bauer K.R., Brown M., Cress R.D., Parise C.A., Caggiano V.: “Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype”. Cancer, 2007, 109, 1721.

[13] Dent R., Trudeau M., Pritchard K.I., Hanna W.M., Kahn H.K., Sawka C.A., et al.: “Triple-negative breast cancer: clinical features and patterns of recurrence”. Clin. Cancer Res., 2007, 13, 4429.

[14] Onitilo A.A., Engel J.M., Greenlee R.T., Mukesh B.N.: “Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival”. Clin Med Res., 2009, 7, 4.

[15] Nag S., Mane A., Gupta S.: “Emerging Prognostic and Predictive Biomarkers for Triple Negative Breast Cancer”. Curr. Breast Cancer Rep., 2014, 6, 275.

[16] Sirohi B., Arnedos M., Popat S., Ashley S., Nerurkar A., Walsh G., et al.: “Platinum-based chemotherapy in triple-negative breast cancer”. Ann Oncol., 2008, 19, 1847.

[17] Silver D.P., Richardson A.L., Eklund A.C., Wang Z.C., Szallasi Z., Li Q., et al.: “Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer”. J. Clin. Oncol., 2010, 28, 1145.

[18] Garrido C., Schmitt E., Candé C., Vahsen N., Parcellier A., Kroemer G.: “HSP27 and HSP70: potentially oncogenic apoptosis inhibitors”. Cell Cycle, 2003, 2, 578.

[19] Guzhova I., Margulis B.: “Hsp70 chaperone as a survival factor in cell pathology”. Int. Rev. Cytol., 2006, 254, 101.

[20] Ciocca D.R., Calderwood S.K.: “Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications”. Cell Stress Chaperones, 2005, 10, 86.

[21] Calderwood S.K., Sherman M.Y., Ciocca D.R.: “Targeting Hsp90 Function to Treat Cancer: Much More to Be Learned”. In: Whitesell L., McLellan C.A. (eds). Heat Shock Proteins in Cancer”: Springer: Netherlands, 2007, 253.

[22] Bonorino C., Souza A.P.: “Hsp70 in tumors: Friend or foe?” In: Whitesell L., McLellan C.A. (eds). Heat Shock Proteins in Cancer”: Springer: Netherlands, 2007, 191.

[23] Lianos G.D., Alexiou G.A., Mangano A., Mangano A., Rausei S., Boni L., Dionigi G., Roukos D.H.: “The role of heat shock proteins in cancer”. Cancer Lett., 2015, 360, 114.

[24] Lemoisson E., Cren H., Goussard J.: “Chromatographic separation of eight progesterone receptor isoforms in human breast tumors, and detection by radioligand and monoclonal antibodies. Association with hsp90 and hsp70 heat shock proteins”. Ann. Biol. Clin. (Paris), 1993, 433.

[25] Ciocca D.R., Clark G.M., Tandon A.K., Fuqua S.A., Welch W.J., McGuire W.L.: “Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications”. J. Natl. Cancer Inst., 1993, 85, 570.

[26] Cornford P.A., Dodson A.R., Parsons K.F., Desmond A.D., Woolfenden A., Fordham M., et al.: “Heat shock protein expression independently predicts clinical outcome in prostate cancer”. Cancer Res., 2000, 60, 7099.

[27] Trieb K., Gerth R., Holzer G., Grohs J., Berger P., Kotz R.: “Antibodies to heat shock protein 90 in osteosarcoma patients correlate with response to neoadjuvant chemotherapy”. Br. J. Cancer, 2000, 82, 85.

[28] Van De Vijver M.J., He Y.D., Van't Veer L.G., Dai H., Hart A.A., Voskuil D.W., et al.: “A gene-expression signature as a predictor of survival in breast cancer”. N. Engl. J. Med., 2002, 34, 1999.

[29] Hwang T.S., Han H.S., Choi H.K., Lee Y.J., Kim Y.J., Han M.Y., Park Y.M.: “Differential, stage-dependent expression of Hsp70, Hsp110 and Bcl-2 in colorectal cancer”. J. Gastroenterol. Hepatol., 2003, 18, 690.

[30] Cappello F., Bellafiore M., David S., Anzalone R., Zummo G.: “Ten kilodalton heat shock protein (HSP10) is overexpressed during carcinogenesis of large bowel and uterine exocervix”. Cancer Lett., 2003, 196, 35.

[31] Cappello F., Bellafiore M., Palma A., David S., Marcianò V., Bartolotta T., Sciume C., Modica G., Farina F., Zummo G.: “60KDa chaperonin (HSP60) is over-expressed during colorectal carcinogenesis”. Eur. J. Histochem., 2003, 47, 105.

[32] Ciocca D.R., Jorge A.D., Jorge O., Milutín C., Hosokawa R., Lestren M.D., et al.: “Estrogen receptors, progesterone receptors and heatshock 27-kD protein in liver biopsy specimens from patients with hepatitis B virus infection”. Hepatology, 1991, 13, 838.

[33] Tauchi K., Tsutsumi Y., Hori S., Yoshimura S., Osamura R.Y., Watanabe K.: “Expression of heat shock protein 70 and c-myc protein in human breast cancer: an immunohistochemical study”. Jpn. J. Clin. Oncol., 1991, 21, 256.

[34] Thor A., Benz C., Moore D., Goldman E., Edgerton S., Landry J., et al.: “Stress response protein (srp–27) determination in primary human breast carcinomas: clinical, histologic, and prognostic correlations”. J. Natl. Cancer Inst., 1991, 83, 170.

[35] Conroy S., Sasieni P., Fentiman I., Latchman D.: “Autoantibodies to the 90kDa heat shock protein and poor survival in breast cancer patients”. Eur. J. Cancer, 1998, 34, 942.

[36] Conroy S., Sasieni P., Amin V., Wang D., Smith P., Fentiman I., Latchman D.: “Antibodies to heat-shock protein 27 are associated with improved survival in patients with breast cancer”. Br. J. Cancer, 1998, 77, 1875.

[37] Lu M., Whelan S.A., He J., Saxton R.E., Faull K.F., Whitelegge J.P., Chang H.R.: “Hydrophobic proteome analysis of triple negative and hormone-receptor-positive-her2-negative breast cancer by mass spectrometer”. Clin. Proteomics, 2010, 6, 93.

[38] Cheng Q., Chang J.T., Geradts J., Neckers L.M., Haystead T., Spector N.L., Lyerly H.K.: “Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer”. Breast Cancer Res., 2012, 14, R62.

[39] Pick E., Kluger Y., Giltnane J.M., Moeder C., Camp R.L., Rimm D.L., Kluger H.M.: “High HSP90 expression is associated with decreased survival in breast cancer”. Cancer Res., 2007, 67, 2932.

[40] Song C.H., Park S.Y., Eom K.Y., Kim J.H., Kim S.W., Kim J.S., Kim L.A.: “Potential prognostic value of heat-shock protein 90 in the presence of phosphatidylinositol-3-kinase overexpression or loss of PTEN, in invasive breast cancers”. Breast Cancer Res., 2010, 12, R20.

[41] Yano, M., Naito Z., Tanaka S., Asano G.: “Expression and roles of heat shock proteins in human breast cancer”. Jpn. J. Cancer Res., 1996, 87, 908.

[42] Zagouri F., Nonni A., Sergentanis T.N., Papadimitriou C.A., Michalopoulos N.V., Lazaris A.C., Patsouris E., Zografos G.C.: “Heat shock protein90 in lobular neoplasia of the breast”. BMC Cancer, 2008, 8, 312.

[43] Pogoda K., Niwińska A., Murawska M., Pieńkowski T.: “Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients”. Med. Oncol., 2013, 30, 388.

[44] Barnes J., Dix D., Collins B., Luft C., Allen J.: “Expression of inducible Hsp70 enhances the proliferation of MCF-7 breast cancer cells and protects against the cytotoxic effects of hyperthermia”. Cell Stress Chaperones, 2001, 6, 316.

[45] Torronteguy C., Frasson A., Zerwes F., Winnikov E., da Silva V.D., Ménoret A., Bonorino C.: “Inducible heat shock protein 70 expression as a potential predictive marker of metastasis in breast tumors”. Cell Stress Chaperones, 2006, 11, 34.

[46] Sun B., Zhang S., Zhang D., Li Y., Zhao X., Luo Y., Guo Y.: “Identification of metastasis-related proteins and their clinical relevance to triple-negative human breast cancer”. Clin. Cancer Res., 2008, 14, 7050.

[47] Bini L., Magi B., Marzocchi B., Arcuri F., Tripodi S., Cintorino M., Sanchez J.C., Frutiger S., Hughes G., Pallini V.: “Protein expression profiles in human breast ductal carcinoma and histologically normal tissue”. Electrophoresis., 1997, 18, 2832-2841.

[48] Isidoro A., Casado E., Redondo A., Acebo P., Espinosa E., Alonso A.M., Cejas P., Hardisson D., Vara J.A.F., Belda-Iniesta C.: “Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis”. Carcinogenesis, 2005, 26, 2095.

[49] Li D.Q., Wang L., Fei F., Hou Y.F., Luo J.M., Zeng R., et al.: “Identification of breast cancer metastasis-associated proteins in an isogenic tumor metastasis model using two-dimensional gel electrophoresis and liquid chromatography-ion trap-mass spectrometry”. Proteomics, 2006, 6, 3352.

[50] Desmetz C., Bibeau F., Boissiere F., Bellet V., Rouanet P., Maudelonde T., et al.: “Proteomics-based identification of HSP60 as a tumor-associated antigen in early stage breast cancer and ductal carcinoma in situ”. J. Proteome Res., 2008, 7, 3830.

[51] Storm F.K., Mahvi D.M., Gilchrist K.W.: “Heat shock protein 27 overexpression in breast cancer lymph node metastasis”. Ann. Surg. Oncol., 1996, 3, 570.

[52] Liebhardt S., Ditsch N., Nieuwland R., Rank A., Jeschke U., Von Koch F., et al.: “CEA-, Her2/neu-, BCRP-and Hsp27-positive microparticles in breast cancer patients”. Anticancer Res., 2010, 30, 1707.

[53] Straume O., Shimamura T., Lampa M.J., Carretero J., Øyan A.M., Jia D., et al.: “Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer”. Proc Natl Acad Sci U S A., 2012, 109, 8699-8704.

[54] Aka J.A., Lin S.X.: “Comparison of functional proteomic analyses of human breast cancer cell lines T47D and MCF7”. PloS One, 2012, 7, e31532.

[55] Lino M.A.M., Palacios-Rodríguez Y., Rodríguez-Cuevas S., Bautista-Piña V., Marchat L.A., Ruíz-García E., Astudillo-de la Vega H., et al.: “Comparative proteomic profiling of triple-negative breast cancer reveals that up-regulation of RhoGDI-2 is associated to the inhibition of caspase 3 and caspase 9”. J Proteomics., 2014, 111, 198- 211.

[56] Hamrita B., Chahed K., Kabbage M., Guillier C.L., Trimeche M., Chaïeb, A., Chouchane L.: “Identification of tumor antigens that elicit a humoral immune response in breast cancer patients' sera by serological proteome analysis (SERPA):. Clin. Chim. Acta, 2008, 393, 95.

[57] Xanthoudakis S., Roy S., Rasper D., Hennessey T., Aubin Y., Cassady R., et al.: “Hsp60 accelerates the maturation of pro-caspase-3 by upstream activator proteases during apoptosis”. EMBO J., 1999, 18, 2049.

[58] Garrido C., Brunet M., Didelot C., Zermati Y., Schmitt E., Kroemer G.: “Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties”. Cell Cycle, 2006, 5, 2592.

[59] Tanabe M., Ishida R., Izuhara F., Komatsuda A., Wakui H., Sawada K., et al.: “The ATPase activity of molecular chaperone HSP60 is inhibited by immunosuppressant mizoribine”. Am. J. Mol. Biol., 2012, 2, 93.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top